New cocktail of cancer drugs tested for safety in advanced tumors
NCT ID NCT03307785
First seen Oct 31, 2025 · Last updated May 01, 2026 · Updated 27 times
Summary
This early-phase study tested the safety of combining multiple cancer drugs (niraparib, TSR-022, bevacizumab, chemotherapy, and TSR-042) in 60 people with advanced or metastatic solid tumors. The goal was to find safe doses for future studies. Participants had different types of cancer and received different drug combinations. The study focused on side effects and dose limits, not on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Scottsdale, Arizona, 85258, United States
-
GSK Investigational Site
Encinitas, California, 92024, United States
-
GSK Investigational Site
San Marcos, California, 92069, United States
-
GSK Investigational Site
Sarasota, Florida, 34232, United States
-
GSK Investigational Site
Canton, Ohio, 44718, United States
-
GSK Investigational Site
Cleveland, Ohio, 44106, United States
-
GSK Investigational Site
Nashville, Tennessee, 37203, United States
-
GSK Investigational Site
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.